{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:26:18Z","timestamp":1787923578334,"version":"build-2784847793"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031688","name":"Pfizer Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study investigates the diagnostic accuracy of cardiac magnetic resonance (CMR) T1 mapping for the evaluation of cardiac amyloidosis (CA) in elderly patients with heart failure (HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We prospectively enrolled consecutive patients aged \u226560\u2005years with symptomatic HF, left ventricular ejection fraction (LVEF) \u2265 40%, increased left ventricular (LV) wall thickness (\u226512\u2005mm), and elevated cardiac biomarkers. All patients underwent standardized CMR, bone scintigraphy, and screening for monoclonal proteins. Primary endpoint was the diagnosis of CA with T1 mapping. The reference standard was a confirmed CA diagnosis by bone scintigraphy. One hundred and twelve patients (median age 81\u2005years, 45% female) were included. CA was diagnosed in 38 patients (34%). Patients with CA showed advanced LV remodelling, indicated by higher LV mass index, lower LVEF, higher native T1 values, and higher extracellular volume fraction (ECV). Diagnostic accuracy on ROC curve analysis was 0.836 for native T1 and 0.904 for ECV. Native T1 &amp;lt; 1303\u2005ms excluded CA. In patients with native T1 \u2265 1303\u2005ms, there was no CA as cause of HF observed if ECV &amp;lt; 30%, while 85% of patients with an ECV 40\u201349% and 100% with ECV \u2265 50% had CA (P &amp;lt; 0.0001). By this approach, contrast application could have been avoided in 33%. A definite confirmation or exclusion of CA by CMR was established in 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In elderly patients with symptomatic HF, LVEF \u2265 40%, LV hypertrophy, and elevated cardiac biomarkers, a CMR approach with native T1 and ECV measurements is useful to identify underlying CA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT04862273 at clinicaltrials.gov.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjimp\/qyag131","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:06:39Z","timestamp":1784721999000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiac magnetic resonance T1 mapping for amyloid cardiomyopathy in patients with heart failure"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7634-0954","authenticated-orcid":false,"given":"Lara","family":"Unger","sequence":"first","affiliation":[{"name":"Department of Cardiology, Leipzig University Hospital , Liebigstrasse 20, Leipzig 04103 ,","place":["Germany"]},{"name":"Central German Heart Alliance ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-2496","authenticated-orcid":false,"given":"Romy","family":"Gessner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leipzig University Hospital , Liebigstrasse 20, Leipzig 04103 ,","place":["Germany"]},{"name":"Central German Heart Alliance ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Stegmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leipzig University Hospital , Liebigstrasse 20, Leipzig 04103 ,","place":["Germany"]},{"name":"Central German Heart Alliance ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hagendorff","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leipzig University Hospital , Liebigstrasse 20, Leipzig 04103 ,","place":["Germany"]},{"name":"Central German Heart Alliance ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig","family":"Tiepolt","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Leipzig University Hospital , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Leipzig University Hospital , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ebel","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Leipzig University Hospital , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-3208","authenticated-orcid":false,"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Leipzig University Hospital , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-9323","authenticated-orcid":false,"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leipzig University Hospital , Liebigstrasse 20, Leipzig 04103 ,","place":["Germany"]},{"name":"Central German Heart Alliance ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-212X","authenticated-orcid":false,"given":"Daniel","family":"Lavall","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leipzig University Hospital , Liebigstrasse 20, Leipzig 04103 ,","place":["Germany"]},{"name":"Central German Heart Alliance ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026082801061967300_qyag131-B1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"2026082801061967300_qyag131-B2","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026082801061967300_qyag131-B3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"2026082801061967300_qyag131-B4","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026082801061967300_qyag131-B5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026082801061967300_qyag131-B6","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026082801061967300_qyag131-B7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082801061967300_qyag131-B8","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026082801061967300_qyag131-B9","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026082801061967300_qyag131-B10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026082801061967300_qyag131-B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","article-title":"Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026082801061967300_qyag131-B12","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","article-title":"Myocardial T1 and ECV measurement","volume":"12","author":"Robinson","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B13","doi-asserted-by":"crossref","first-page":"e003285","DOI":"10.1161\/CIRCIMAGING.115.003285","article-title":"T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study","volume":"8","author":"Hinojar","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ejhf.2997","article-title":"Diagnosis and management of patients with left ventricular hypertrophy: role of multimodality cardiac imaging. A Scientific Statement of the Heart Failure Association of the ESC","volume":"25","author":"Moura","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026082801061967300_qyag131-B15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00392-022-02005-2","article-title":"Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy","volume":"112","author":"Lavall","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026082801061967300_qyag131-B20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026082801061967300_qyag131-B21","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026082801061967300_qyag131-B22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026082801061967300_qyag131-B23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/13506129.2012.684810","article-title":"New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis","volume":"19","author":"Leone","year":"2012","journal-title":"Amyloid"},{"key":"2026082801061967300_qyag131-B24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjci\/jeac215","article-title":"Utility of cardiovascular magnetic resonance in patients with stable troponin elevation","volume":"24","author":"Ananthakrishna","year":"2023","journal-title":"Eur Heart J\u2014Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026082801061967300_qyag131-B26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2025.10.054","article-title":"Myocardial amyloid burden in transthyretin amyloidosis","volume":"87","author":"Sheikh","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026082801061967300_qyag131-B27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026082801061967300_qyag131-B28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","article-title":"Myocardial amyloidosis","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082801061967300_qyag131-B29","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.jchf.2025.102528","article-title":"Cardiac magnetic resonance imaging vs coronary angiography as primary strategy in newly diagnosed heart failure","volume":"13","author":"G\u00fcder","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026082801061967300_qyag131-B30","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Imaging Methods and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjimp\/advance-article-pdf\/doi\/10.1093\/ehjimp\/qyag131\/69857893\/qyag131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/3\/qyag131\/69857893\/qyag131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/3\/qyag131\/69857893\/qyag131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:45:14Z","timestamp":1787921114000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjimp\/article\/doi\/10.1093\/ehjimp\/qyag131\/8740376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjimp\/qyag131","relation":{},"ISSN":["2755-9637"],"issn-type":[{"value":"2755-9637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"qyag131"}}